Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of IXT-m200 in Healthy Participants
NCT05027451Phase 1Completed
- Sponsor
- InterveXion Therapeutics
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in methamphetamine use disorder (MUD) and Methamphetamine Toxicity comparing IXT-m200 with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-related Adverse Events (AEs) at Day 127. Started Oct 2021; status: completed.
02
Drugs
devextinetug
03
Conditions
methamphetamine use disorder (MUD)Methamphetamine Toxicity
Beyond the preview
Go deeper on NCT05027451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027451.